Ultragenyx Pharmaceutical Inc.
Initiate Phase 3 study for DTX401
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Jan 2021
- Due
- 30 Jun 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Ultragenyx expects to initiate Phase 3 studies for DTX401 in the first half of 2021”
What we found
Evidence strength A What the grades mean
The company did not initiate the Phase 3 study for DTX401 by the first half of 2021, as filings from August 2021 indicate the study was still in the process of being initiated.
-
A Ultragenyx Pharmaceutical Inc. 10-Q filed 2021-08-03
“We are currently in the process of initiating a Phase 3 study” ✓ confirmed on the page
Market reaction: the shares moved +10.8% against the S&P 500 over the three sessions around the disclosure (2 Aug 2021 to 5 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 3 study for DTX401
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Ultragenyx Pharmaceutical Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-RARE-021346 · Corrections policy